Crypto and Stocks: MicroStrategy Buys Bitcoin as HIMS and Tesla Make Moves

MicroStrategy boosts Bitcoin holdings to 738,731 BTC. HIMS stock rises on a Novo Nordisk partnership for GLP-1 drugs, while Tesla faces NHTSA data deadlines and Blue Owl navigates private credit sector pressures.

MicroStrategy Expands Bitcoin Treasury Strategy

MSTR most current substantial Bitcoin(CRYPTO: BTC) procurement announced on March 9 was in emphasis as Approach bought 17,994 BTC for approximately $1.28 billion, at an average cost of $70,946 per coin), funded mainly with ordinary shares sales and at-the-market offerings of its STRC favored shares, increasing complete holdings to 738,731 BTC, representing concerning 3.5% of Bitcoin’s supply and obtained for about $56 billion general. This action, teased by Executive Chairman Michael Saylor with “The 2nd Century Starts,” strengthened the firm’s relentless BTC treasury technique amidst a difficult macro environment where Bitcoin traded around $69,000–$71,000.

OWL stock was in focus amid the continuous pressure in the private credit scores sector, with the supply continuing its sharp decrease. Secret growths consisted of the Financial Times reports on Glendon Resources Management criticizing Blue Owl and peers for potentially obscuring profile weak points with filled with air financing assessments in funds like Blue Owl Capital Firm, elevating worries of an impending sharp improvement in debt markets– triggering OWL to comfort financiers in a personal seminar that its recent $1.4 billion loan sale throughout three funds had no surprise rewards, backstops, or special terms.

Health Partnerships and Regulatory Scrutiny

HIMS news stories from March 9 to March 13, 2026, were dominated by the company’s blockbuster partnership news with Novo Nordisk A/S(NYSE: NVO), which sent out the supply soaring. Under the offer, Hims & Hers will certainly supply Novo Nordisk’s top quality GLP-1 weight-loss drugs like Ozempic and Wegovy on its telehealth platform beginning later in March, while ceasing promo of compounded variations– settling a prior license infringement lawsuit from Novo and eliminating a significant lawful overhang amidst regulative analysis on compounded GLP-1s.

TSLA had a March 9 deadline for submitting comprehensive Complete Self-Driving (FSD) collision and website traffic infraction information to the NHTSA, component of a recurring investigation into ~ 58 incidents across numerous vehicles and 14 reported robotaxi accidents because mid-2025– developing governing overhang and examination on Tesla’s freedom story, though no immediate unfavorable after effects or brand-new disclosures emerged post-deadline, with belief blended on whether the data submission boosted or pressured the stock’s AI/robotaxi assessment costs. More comprehensive bearish stress came from a Reuters record on March 11 highlighting analysts lowering 2026 delivery growth forecasts to about 3.8%.

The stock had a 52-week range of $214.25 to $498.83, trading around $395 to $400 per share, since the publication of this write-up. It advanced by 59.22% throughout the years and down 0.23% over the last six months.